Sci-Engi-Medco Solutions Inc. Awarded SBIR Phase 1 NCI Contract to Study Its Lead Molecules in Preclinical Model of Triple Negative Breast Cancer

ST. CHARLES, Mo., Jan. 12, 2018 /PRNewswire/ — Sci-Engi-Medco Solutions Inc. (SEMCO), a private cancer drug discovery and development company that explores its proprietary small molecule anticancer agent technology, announced today that it has been awarded a Small Business Innovation…

Powered by WPeMatico

Leave a Reply

Your email address will not be published.